All In MedTech

FDA Clearance Tracker · P130030

REBEL PLATINUM CHROMIUM CORONARY STENT SYSTEM MONORAIL AND OVER THE WIRE

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Mar 10, 2026 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Mar 10, 2026

Approved

Time to decision

4,453 days

Received Dec 30, 2013. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P130030
Device name
REBEL PLATINUM CHROMIUM CORONARY STENT SYSTEM MONORAIL AND OVER THE WIRE
Applicant location
Maple Grove, MN
Received
Dec 30, 2013
Decided
Mar 10, 2026
Decision
Approved
Supplements
75 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code MAF

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE REBEL PLATINUM CHROMIUM CORONARY STENT SYSTEM (MONORAIL AND OVER-THE-WIRE). THIS DEVICE IS INDICATED FOR IMPROVING CORONARY LUMINAL DIAMETER IN PATIENTS WITH DE NOVO LESIONS <= 28 MM IN LENGTH IN NATIVE CORONARY ARTERIES WITH A REFERENCE VESSEL DIAMETER (RVD) OF >= 2.25 TO >= 4.50 MM.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code MAF. The earliest in FDA's data is P910030, decided Feb 8, 1993.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Boston Scientific Corp

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.